scholarly journals Hydrochlorothizide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo

2019 ◽  
Vol 12 (2) ◽  
pp. bcr-2017-223528 ◽  
Author(s):  
Leo E Reap ◽  
Cassandra Rodd ◽  
Jose Larios ◽  
Michael Marshall
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Cutaneous Adverse Reaction ◽  
Common Causes ◽  
Erythematous Plaques ◽  
Exanthematous Pustulosis

Acute generalised exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction characterised by the appearance of erythematous plaques and papules with overlying non-follicular pinpoint pustules. Drugs are the cause of AGEP in approximately 90% of cases. The most common causes include anti-infective agents (aminopenicillins, quinolones, antibacterial sulfonamides and terbinafine), antimalarials and diltiazem. To the best of our knowledge, to date there has only been one report of hydrochlorothiazide-induced AGEP. There has never been a case report of losartan-induced AGEP. Here, we present a case of AGEP that is the second case purportedly caused by hydrochlorothiazide.

scholarly journals Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis

Medicina ◽  
2021 ◽  
Vol 57 (10) ◽  
pp. 1004
Author(s):  
Morgan Sussman ◽  
Anthony Napodano ◽  
Simo Huang ◽  
Abhirup Are ◽  
Sylvia Hsu ◽  
...  
Keyword(s):  
Adverse Reaction ◽  
Clinical Course ◽  
Pustular Psoriasis ◽  
Topical Steroids ◽  
Inflammatory Disorder ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Cutaneous Adverse Reaction ◽  
History Of ◽  
Exanthematous Pustulosis ◽  
Crucial Part

The similarity between pustular psoriasis (PP) and acute generalized exanthematous pustulosis (AGEP) poses problems in the diagnosis and treatment of these two conditions. Significant clinical and histopathologic overlap exists between PP and AGEP. PP is an inflammatory disorder that has numerous clinical subtypes, but all with sterile pustules composed of neutrophils. AGEP is a severe cutaneous adverse reaction that is also characterized by non-follicular sterile pustules. Clinical features that suggest a diagnosis of PP over AGEP include a history of psoriasis and the presence of scaling plaques. Histologically, eosinophilic spongiosis, vacuolar interface dermatitis, and dermal eosinophilia favor a diagnosis of AGEP over PP. Importantly, PP and AGEP vary in clinical course and treatment. PP treatment involves topical steroids, oral retinoids, and systemic immunosuppressants. Newer therapies targeting IL-36, IL-23, IL-1, and PDE-4 have been investigated. The removal of the offending agent is a crucial part of the treatment of AGEP.

Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine: First Case Report in Canada and Review of the Literature

2013 ◽  
Vol 17 (6) ◽  
pp. 414-418 ◽  
Author(s):  
Kristy Bailey ◽  
Daniel Mckee ◽  
Judy Wismer ◽  
Neil Shear
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Drug Eruption ◽  
Spontaneous Resolution ◽  
Review Of The Literature ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Pathologic Findings ◽  
Complicated Course ◽  
Exanthematous Pustulosis

Background: Acute generalized exanthematous pustulosis (AGEP) is a rare drug eruption presenting with an acute, extensive formation of nonfollicular sterile pustules on an erythematous and edematous base. Typically, the rash is accompanied by fever and leukocytosis, with spontaneous resolution in < 15 days. The incidence of AGEP is estimated at one to five cases per million people per year. Only 18% of these are from nonantibiotics. Hydroxychloroquine (HCQ) is an antimalarial agent that is also used to treat various dermatologic and rheumatologic conditions. Objective: We report the first observation in Canada of a patient with AGEP induced by HCQ. Methods and Results: AGEP was diagnosed in a 48-year-old female who had been taking HCQ for 2 weeks and then developed a diffuse erythematous and edematous pustular eruption. Clinical and pathologic findings were consistent with a diagnosis of AGEP. The patient was treated with steroids and supportive measures. The rash resolved after 18 days and a complicated course in hospital. Conclusion: AGEP is a rare drug eruption, usually to antibiotics. We report the first case in Canada of AGEP as an adverse reaction to HCQ. Clinicians should keep in mind the possibility of this severe skin eruption.

scholarly journals Stevens-Johnson syndrome induced by phenytoin: a case report

2016 ◽  
Vol 6 (1) ◽  
pp. 208
Author(s):  
Lalkota Prakash Bhanu ◽  
Kumara Swamy M. ◽  
Mohammed Nasiruddin ◽  
Naveen H. D. ◽  
Rajesh Venkataraman
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Toxic Epidermal Necrolysis ◽  
Antiepileptic Drugs ◽  
Stevens Johnson Syndrome ◽  
Drug Reactions ◽  
Cutaneous Adverse Reaction ◽  
Johnson Syndrome ◽  
Life Threatening ◽  
Grade 3

Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN) are rare (one to two per 10,00,00 population per year) but life threatening adverse drug reactions. Antiepileptic drugs-induced Stevens-Johnson syndrome (SJS) is a life-threatening severe cutaneous adverse reaction, amongst anti-epileptics; carbamazepine and phenytoin are the major culprits. We report here a case of SJS due to phenytoin (CTC vs 2 Grade 3).

A Case of Acute Generalized Exanthematous Pustulosis by Cefixime with Oral Mucosal Involvement

2020 ◽  
Vol 15 (3) ◽  
pp. 236-239 ◽  
Author(s):  
Ramanachary Namoju ◽  
Mohammed Ismail ◽  
Vinay Kumar Golla ◽  
Tejaswini Bamini ◽  
Thanmaya Lakshmi Akarapu ◽  
...  
Keyword(s):  
Case Report ◽  
Management Strategies ◽  
Beta Lactam ◽  
Mucosal Membrane ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Cutaneous Adverse Reaction ◽  
Mucosal Involvement ◽  
Lactam Antibiotic ◽  
Exanthematous Pustulosis

Acute generalized exanthematous pustulosis (AGEP) is a rare severe cutaneous adverse reaction characterized by the development of numerous sterile and non-follicular pustules on an erythematous base with no or minimal mucous membrane involvement associated with fever and leucocytosis. Cefixime is a cephalosporin-type beta-lactam antibiotic commonly used for the management of several infections. The Cefixime-induced AGEP cases are known to be rare. Here, we present the case report of a 26-year old female who developed Cefixime-induced AGEP with mucosal membrane involvement. To the best of our knowledge, this is the first case to report the mucosal membrane involvement in Cefixime-induced AGEP. We are presenting this case report to draw the attention on the existence and plethora of symptoms of Cefixime-induced AGEP hoping that the clinicians will reckon these in their differential diagnosis and implement the appropriate management strategies for this rare adverse event in their clinical practice.

scholarly journals Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis

2019 ◽  
Vol 2019 ◽  
pp. 1-3
Author(s):  
Aikaterini Kyriakou ◽  
Sofia-Chrysovalantou Zagalioti ◽  
Aikaterini Patsatsi ◽  
Nikiforos Galanis ◽  
Elizabeth Lazaridou
Keyword(s):  
Adverse Reaction ◽  
Laboratory Tests ◽  
Groin Pain ◽  
Metastatic Breast ◽  
Intravenous Therapy ◽  
E Coli ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Cutaneous Adverse Reaction ◽  
Severe Infections ◽  
Exanthematous Pustulosis

Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous adverse reaction mainly attributed to antibiotics. It is characterized by numerous, nonfollicular, sterile pustules, arising on an exanthematous and edematous base. It is a serious adverse reaction accompanied by fever and leukocytosis. Piperacillin/tazobactam is indicated for the treatment of patients with moderate to severe infections. Herein is reported a case of AGEP caused by piperacillin/tazobactam. A 78-year-old woman with metastatic breast cancer was presented to the emergency department reporting fever and groin pain. The laboratory analysis and more specifically urine cultivation showed a urinary tract infection by E. coli with sensitivity to piperacillin/tazobactam. She had no known allergies. She was started on intravenous piperacillin/tazobactam; she improved clinically on the second day, but on the fourth day of intravenous therapy, she developed extensive pustular rash on the folds and anterior proximal thighs, accompanied by fever and neutrophilia. Piperacillin/tazobactam administration was interrupted and she was given prednisolone for ten days. The patient improved clinically and her laboratory tests returned to normal after two weeks. AGEP is an uncommon side effect of piperacillin/tazobactam treatment and there are few cases reported.

scholarly journals PHẢN ỨNG DA NẶNG DO THUỐC

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Nguyen Van Khiem ◽  
Le Thi Minh Huong
Keyword(s):  
Adverse Reaction ◽  
Drug Reaction ◽  
Toxic Epidermal Necrolysis ◽  
Drug Eruption ◽  
Fixed Drug Eruption ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Cutaneous Adverse Reaction ◽  
Fixed Drug ◽  
Exanthematous Pustulosis

Phản ứng da nặng (Severe Cutaneous Adverse Reaction, SCAR) do thuốc là một nhóm các phản ứng dị ứng thuốc gây tổn thương nghiêm trọng đến da và niêm mạc, trong những trường hợp nặng có thể ảnh hưởng đến các cơ quan nội tạng, thậm chí gây tử vong. Ngoài thuốc, một số tác nhân nhiễm trùng như Mycoplasma pneumoniacũng có thể gây ra SCAR, đặc biệt ở trẻ em. Trong bài này, xin được tập trung vào SCAR do thuốc. SCAR bao gồm các hội chứng sau: Hội chứng Steven – Johnson (SJS) Hội chứng hoạt tử thượng bì nhiễm độc (Toxic Epidermal Necrolysis, TEN, trước đây còn được gọi là hội chứng Lyell) Hội chứng chuyển tiếp giữa SJS và TEN (SJS/TEN overlap) Hội chứng phản ứng với thuốc có triệu chứng toàn thân và tăng bạch cầu ái toan (Drug Reaction with Eosinophilia and Systemic Symtoms, DRESS). Ban mụn mủ toàn thân cấp tính (Acute Generalized Exanthematous Pustulosis, AGEP). Gần đây, phát ban cố định do thuốc thể bọng nước lan tỏa (Generalized Bullous Fixed Drug Eruption, GBFDE) cũng được một số bác sĩ xếp vào SCAR. Tuy nhiên GBFDE thường ít nguy hiểm hơn cũng như rất hiếm gặp ở trẻ em. Trong các hội chứng trên, SJS, TEN và hội chứng chuyển tiếp SJS/TEN được cho là cùng một bệnh với các mức độ nặng khác nhau. Trong bài này, chúng được kí hiệu chung là SJS-TEN

Abstract #230: Bullous Pemphigoid-Adverse Reaction to Linagliptin (Tradjenta): A Case Report

2015 ◽  
Vol 21 ◽  
pp. 38-39
Author(s):  
Issac Sachmechi ◽  
Raya Galibov ◽  
Venkat Dirish Arukala
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Bullous Pemphigoid
Sign in / Sign up

Export Citation Format

Share Document